# Natural Killer(NK) Cell Therapy in r/r AML

> **NCT05665114** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 18 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** QN-030a
- **DRUG:** Cyclophosphamid
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** VP-16

## Key facts

- **NCT ID:** NCT05665114
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-24
- **Primary completion:** 2023-12-24
- **Final completion:** 2025-12-24
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665114, "Natural Killer(NK) Cell Therapy in r/r AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05665114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*